These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
510 related articles for article (PubMed ID: 16086652)
21. [Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children]. Balwierz W Przegl Lek; 2004; 61 Suppl 2():89-94. PubMed ID: 15686055 [TBL] [Abstract][Full Text] [Related]
22. Caspofungin: first approved agent in a new class of antifungals. Johnson MD; Perfect JR Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003 [TBL] [Abstract][Full Text] [Related]
23. New antifungal drugs and new clinical trials: interpreting results may be difficult. Girmenia C; Martino P Curr Opin Oncol; 2003 Jul; 15(4):283-8. PubMed ID: 12874505 [TBL] [Abstract][Full Text] [Related]
24. Caspofungin: a review of its use in the treatment of fungal infections. McCormack PL; Perry CM Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025 [TBL] [Abstract][Full Text] [Related]
25. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Keating G; Figgitt D Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760 [TBL] [Abstract][Full Text] [Related]
26. Micafungin: a therapeutic review. Higashiyama Y; Kohno S Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200 [TBL] [Abstract][Full Text] [Related]
27. Caspofungin: the first representative of a new antifungal class. Letscher-Bru V; Herbrecht R J Antimicrob Chemother; 2003 Mar; 51(3):513-21. PubMed ID: 12615851 [TBL] [Abstract][Full Text] [Related]
33. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Spanakis EK; Aperis G; Mylonakis E Clin Infect Dis; 2006 Oct; 43(8):1060-8. PubMed ID: 16983621 [TBL] [Abstract][Full Text] [Related]
34. Antifungal treatment in pediatric patients. Zaoutis TE; Benjamin DK; Steinbach WJ Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422 [TBL] [Abstract][Full Text] [Related]
35. An update on the use of antifungal agents. Martinez R J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750 [TBL] [Abstract][Full Text] [Related]
36. Anidulafungin: a new echinocandin for the treatment of fungal infections. Cohen-Wolkowiez M; Benjamin DK; Steinbach WJ; Smith PB Drugs Today (Barc); 2006 Aug; 42(8):533-44. PubMed ID: 16969430 [TBL] [Abstract][Full Text] [Related]
37. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. Koss T; Bagheri B; Zeana C; Romagnoli MF; Grossman ME J Am Acad Dermatol; 2002 Jun; 46(6):945-7. PubMed ID: 12063497 [TBL] [Abstract][Full Text] [Related]
38. Micafungin: the US perspective. Zaas AK; Steinbach WJ Expert Rev Anti Infect Ther; 2005 Apr; 3(2):183-90. PubMed ID: 15918776 [TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414 [TBL] [Abstract][Full Text] [Related]
40. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Espinel-Ingroff A Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]